Evogene Ltd.

Welcome to Evagen's fourth quarter results conference call. All participants are present in listen-only mode. Following management's formal presentation, we will open the question and answer session. As a reminder, this conference is being recorded March 6, 2025. Before we begin, I would like to caution that certain statements made during this earnings conference call by Evagen's management will constitute forward-looking statements. that relate to future events. This presentation contains forward-looking statements relating to future events, and Evagen LTD, the company, may from time to time make other statements regarding our outlook or expectations for future financial or operating results and or other matters regarding or affecting us that are considered forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. and other securities laws as amended statements that are not statements of historical fact may be deemed to be forward looking statements. Such forward looking statements may be identified by the use of such words as believe, expect, anticipate, should, planned, estimated, intend, and potential or words of similar meaning. We are using forward looking statements in this presentation when we discuss our value drivers commercialization and production efforts and timing product development and launches, estimated market sizes and milestones, pipelines as well as our capabilities and technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expected or implied by such forward-looking statements due to a variety of factors. many of which are beyond our control, including, without limitation, the current war between Israel-Hamas and Hezbollah, and any worsening of the situation in Israel, such as further mobilizations or escalation in the northern border of Israel, and those risks described in greater detail in Evagen's annual report on Form 20-S, and in other information Evagen files and furnishes with the Israel Securities Authorities and U.S. Securities and Exchange Commission. including those factors under the heading risk factors. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections, and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell or any solicitation of any invitation or offer to purchase or subsidize for any securities of Evogen or the company, nor shall the information or any part of it or the fact of its distribution form the basis of or be relied on in connection with any action, contract, commitment, or relating thereto or to the securities of Evagen or the company. The trademarks included herein are property of the owners hereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. With us on the line will be Yaron Eldad, CFO of Evogen and Ofer Habib, President and CEO of Evogen. Now I will turn the call over to Ofer Habib. Mr. Habib, please go ahead.

Good day, everyone. In today's conference call, I would like to begin by welcoming Nirni Morodi as Evogen's new chairman of the board. I will continue with a review of the financial and business highlights for the fourth quarters and the entire year 2024, followed by an overview of Evogen's current activities. I will then conclude with our subsidiaries' targets for 2025. After my remarks, Yaron Eldad, Evogen's CFO, will provide financial update on Q4 and the entire year 2024. We will then open a Q&A session. Today, Evogen formally announced a change in the chair position in which Nir Nimrodi, who served as a board member for the past two and a half years, will now serve as an active chairperson, replacing Sarit Firon, who will now act as a board member. I warmly welcome Nir Nimrodi as Evogen's new chairman of the board, and I'm looking forward to closely working alongside him. I would like to use this opportunity to thank Sarit Firon for guiding Avogen's board and management over the last three and a half years and I'm looking forward to have continued support of the company as a board member. Nir Nimrod is here with us and I ask him to say some introductory words.

Thank you, Ofer. I'm honored to assume the role of chairman and would like to thank Sarit for her valuable contributions. I'm happy she will continue in her capacity as a board member. I'm really excited about the opportunities that lie ahead for Evogen. We believe that the company holds several assets and subsidiaries with potential to generate significant value for both Evogen and its shareholders. I would like to emphasize this last remark again. We're committed to unlocking this value within this year and anticipate achieving it in a capital efficient manner. Evergen has been at the forefront of leveraging advanced computational capabilities to drive product innovation for the past two decades. With the growing potential of AI, we plan to further expand our expertise to accelerate the drug discovery process and maximize the value we bring to this field. Lastly, I have spent the last 25 years in the life science space and was instrumental in generating significant shareholders' value in both public and private companies. I'm eager to get started to do the same with Evogen's team. Thank you.